Patents by Inventor Dirk Block
Dirk Block has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190279770Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.Type: ApplicationFiled: October 12, 2018Publication date: September 12, 2019Applicants: Roche Diagnostics Operations, Inc., Institut Lorrain du Coeur et des Vaisseaux Louis MathieuInventors: Dirk Block, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Faiez Zannad, Patrick Rossignol
-
Publication number: 20190277861Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
-
Patent number: 10345315Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.Type: GrantFiled: September 23, 2016Date of Patent: July 9, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
-
Publication number: 20190154706Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.Type: ApplicationFiled: January 25, 2019Publication date: May 23, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Patent number: 10234462Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.Type: GrantFiled: January 26, 2012Date of Patent: March 19, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
-
Patent number: 10234464Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.Type: GrantFiled: February 26, 2016Date of Patent: March 19, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20180364248Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Martin Hund, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Dirk Block, Johann Karl
-
Publication number: 20180313850Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.Type: ApplicationFiled: July 5, 2018Publication date: November 1, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Julian Braz, Hans-Peter Brunner, James Creeden, Hans-Joerg Loyda, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Publication number: 20180231570Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.Type: ApplicationFiled: April 2, 2018Publication date: August 16, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Andrea Horsch, Birgit Klapperich, Dirk Block, Alfred Engel, Johann Karl, Rosemarie Kientsch-Engel, Ekaterina Manuilova, Christina Rabe, Sandra Rutz, Monika Soukupova, Ursula-Henrike Wienhues-Thelen, Peter Kastner, Edelgard Anna Kaiser
-
Publication number: 20180196067Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.Type: ApplicationFiled: March 5, 2018Publication date: July 12, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
-
Patent number: 9868756Abstract: The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the nucleic acid is bound to a solid phase during the deamination and/or desulfonation step of the bisulfite reaction. The solid phase is preferably a material comprising glass or silica, more preferably a glass fleece, glass membrane or a magnetic glass particle. Further, the use of a solid phase for binding a nucleic acid during the deamination and/or desulfonation step of the bisulfite reaction is disclosed and a kit containing a bisulfite reagent and a solid phase.Type: GrantFiled: August 24, 2015Date of Patent: January 16, 2018Assignee: EPIGENOMICS AGInventors: Christine Markert-Hahn, Dirk Block
-
Publication number: 20170227552Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.Type: ApplicationFiled: April 28, 2017Publication date: August 10, 2017Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
-
Publication number: 20170074892Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.Type: ApplicationFiled: November 23, 2016Publication date: March 16, 2017Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20170016918Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: ApplicationFiled: October 5, 2016Publication date: January 19, 2017Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20170010283Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.Type: ApplicationFiled: September 23, 2016Publication date: January 12, 2017Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
-
Publication number: 20160334419Abstract: The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention.Type: ApplicationFiled: July 27, 2016Publication date: November 17, 2016Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
-
Patent number: 9394332Abstract: The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the nucleic acid is bound to a solid phase during the deamination and/or desulfonation step of the bisulfite reaction. The solid phase is preferably a material comprising glass or silica, more preferably a glass fleece, glass membrane or a magnetic glass particle. Further, the use of a solid phase for binding a nucleic acid during the deamination and/or desulfonation step of the bisulfite reaction is disclosed and a kit containing a bisulfite reagent and a solid phase.Type: GrantFiled: August 25, 2003Date of Patent: July 19, 2016Assignee: Epigenomics AGInventors: Christine Markert-Hahn, Dirk Block
-
Publication number: 20160169911Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.Type: ApplicationFiled: February 26, 2016Publication date: June 16, 2016Inventors: Dirk Block, Hanspeter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
-
Publication number: 20160146836Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.Type: ApplicationFiled: January 27, 2016Publication date: May 26, 2016Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Dirk Block, Hendrik Huedig, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Sara Arab
-
Publication number: 20160068888Abstract: The present application is directed to a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e. methylated and non-methylated cytosines, whereby the nucleic acid is bound to a solid phase during the deamination and/or desulfonation step of the bisulfite reaction. The solid phase is preferably a material comprising glass or silica, more preferably a glass fleece, glass membrane or a magnetic glass particle. Further, the use of a solid phase for binding a nucleic acid during the deamination and/or desulfonation step of the bisulfite reaction is disclosed and a kit containing a bisulfite reagent and a solid phase.Type: ApplicationFiled: August 24, 2015Publication date: March 10, 2016Inventors: Christine Markert-Hahn, Dirk Block